South Korean molecular diagnostics firm Seegene Inc. has forged a partnership with Spanish diagnostics leader Werfen to establish a joint venture in Spain. The collaboration, pending regulatory approvals, is expected to launch in the first half of 2025 as part of Seegene’s global technology-sharing initiative.
The new entity, Werfen-Seegene, will focus on developing PCR diagnostic tests for infectious diseases, antimicrobial resistance, and emerging health challenges specific to the region. By leveraging Werfen’s local infrastructure and Seegene’s syndromic PCR technology, the venture aims to address Spain’s healthcare needs more effectively.
Spain, Europe’s fourth-largest in vitro diagnostics market, will serve as a strategic hub for potential expansion into European and global markets. The partnership is poised to accelerate product development and secure CE-IVDR approval for new diagnostic solutions.
Seegene’s CEO, Dr. Jong-Yoon Chun, expressed high expectations for the collaboration, emphasizing its role in accelerating the global expansion of the company’s technology-sharing initiative. The move follows Seegene’s earlier partnership with Hylabs in Israel and strategic alliances with Microsoft and Springer Nature to enhance product development and innovation in PCR diagnostics.
